What are the lessons from Telangana blast?
What happened?
A four-member committee is investigating the cause of the explosion. The committee is led by B. Venkateshwar Rao, emeritus scientist at CSIR-IICT, and includes T. Prathap Kumar, chief scientist at CSIR-IICT; Surya Narayana, retired scientist at CSIR-CLRI; and Santosh Ghuge, safety officer at CSIR-NCL, Pune. While the cause is being investigated, the pharmaceutical company has issued a statement, 'The accident was not caused by the reactor explosion.'
Sigachi Industries was incorporated in 1989 and was in the business of manufacturing microcrystalline cellulose. This is nothing more than refined wood pulp or powder. This powder is shaped into tablets and serves as an excipient or a non-reactive carrier of medicine. The wood pulp or slurry is processed in a spray dryer that strips it of moisture using hot air. Once processed like this, the wood pulp turns into a fine powder or microcrystalline cellulose. This fine powder is suspected to have blown up on that fateful Monday morning. One of the first such 'dust explosions' recorded was in Turin in Italy in 1785 when a boy working with flour in a bakery created a cloud of flour that got lit by the lamplight. Two persons, including the boy, were injured. There is a long record of similar dust explosions in flour mills, coal mines, and grain silos killing dozens across the world. Fire forensic experts say the blast at Sigachi was a dust explosion considering the scale of damage, raw materials used and processes involved. Initially, the explosion was suspected to be a Boiling Liquid Expanding Vapour Explosion, a technical term regarding the pressure built up inside the reactor. But this has been ruled out by the company, as well as experts.
Was there a regulatory failure?
The laxity of the regulatory framework was stark on the day of the explosion. When fire department and emergency personnel rushed to the site they did not have any information about what they were up against. The State and central pollution control boards mandate a board outside factory premises listing details about the pollution potential of the institution and factory operations. The fire fighting and disaster rescue operations are guided by this information. The green board or environment display boards outside the Sigachi Industries did not have proforma environmental data leaving fire and disaster rescue workers clueless about the nature of material involved and how to douse the fire. A tough regulatory framework with periodic check-ups would have ensured that information was available for a faster emergency response.
This incident comes close on the heels of other serious accidents in pharmaceutical firms in India. Six persons were killed in Sangareddy in the SB Organics factory in 2024, 17 were killed in August 2024 in Anakapalli in Andhra Pradesh, and two were killed in Parawada, Andhra Pradesh in June 2025.
What are the implications for the sector?
An American investments and real estate company in its April 2025 report said: 'Telangana has emerged a pivotal contributor to India's life sciences landscape accounting for approximately one third of the country's pharmaceutical production, one fifth of pharmaceutical exports, and one third of global vaccine production. The State's position as a pharmaceutical manufacturing hub has attracted significant investments, with over $1.49 billion channelled into the life sciences sector over the past four years.' It also analysed the role of Hyderabad in this scheme of things. Over 20 life sciences and medical technology incubators are located in Hyderabad, which is the highest concentration in the country.
India, with Telangana as its hub, has emerged as a powerhouse in the pharmaceutical sector. But safety and quality concerns have dogged smaller pharmaceutical firms. The U.S. is one of the biggest markets for Indian medical exports that is regulated by the U.S. Food and Drug Administration (FDA). The United States Pharmacopeia-National Formulary has a set of standards that regulate identity, strength, quality, purity, and packaging and labelling through the chain of manufacture and use. To keep being plugged into this profitable market, the standards have to match.
Safety is one of the key aspects of branding for the pharmaceutical industry that helps build trust among customers. Any laxity in any aspect of the drug processing has a cascading effect for the company as well as the industry. At stake is not just the safety of one factory but the systems and workflow that are hallmarks of stable and safe drug production. Two books, The Truth Pill - The Myth of Drug Regulation in India and Bottle of Lies: Ranbaxy and the Dark Side of Indian Pharma, by Dinesh S. Thakur and Prashant Reddy T. and Katherine Eban respectively have chronicled the regulatory leeway, and documented the dangerous practices resorted to by Indian pharma firms to keep costs low and profit margins high.
What about pollution control norms?
Hyderabad and Telangana's pharmaceutical industry growth has been aided by lax zoning and regulatory norms. Industrial areas have to be necessarily away from residential areas. The IDA Pashamylaram was established in the early 1980s drawing some of the biggest pharmaceutical firms to the area, away from Balanagar and Patancheru that led the initial growth of the industry in Hyderabad. The initially isolated industrial area is now surrounded by residential areas. In the absence of robust and reliable public transport, worker colonies have cropped up close to the factories and industrial area. This affects the livelihood and health of people in the industrial cluster and surrounding areas.
Environmentalists have documented how tonnes of toxic chemicals and effluents have been released into the ground and into water bodies around the region. The Musi River remains highly polluted with a study on 'Pharmaceutical pollution of the world's rivers' placing it in the 22nd position worldwide in terms of concentration of active pharmaceutical ingredients. This high pollution is linked to poor waste water management infrastructure, and pharmaceutical manufacturing processes. The chemicals in the water have also been linked to a rise in antimicrobial resistance.
What next?
The pharmaceutical sector holds the potential to attract investments and create high employment opportunities in Hyderabad and other places in India. To capitalise on this potential, India must establish a robust regulatory framework. The explosions and accidents are loud warning signs for the industry and the country.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
11 hours ago
- Time of India
Stable forests key to south India's unique biodiversity
HYDERABAD: A mix of stable tropical forests and ancient climate changes led to peninsular India's unique biodiversity over millions of years, according to a study by researchers at the CSIR-Centre for Cellular and Molecular Biology in Hyderabad. Tired of too many ads? go ad free now By examining 33 groups of animals and plants, scientists discovered that some species slowly evolved thanks to long-term ecosystem stability, while others were shaped by drastic changes in climate and landscape between 11 and 3 million years ago. Peninsular India extends from the Aravalli mountains southwards, including the Satpuras and Vindhyas, the Eastern Ghats, the Deccan Plateau and global biodiversity hotspot of Western Ghats. It harbours highly diverse groups of animal and plant species, many of which do not occur anywhere else in the world. The study published in Ecology Letters uncovered how species evolved and disappeared across South Asia and the wider Asian region. By analysing the 33 well-studied groups of animals and plants using mathematical models, the team traced patterns of species formation (speciation) and loss (extinction) across the region. "Each of the groups comprises closely related endemic species and a common ancestor that existed at some point in time. Through millions of years, their descendants spread across the landscape and diversified into multiple species, many of which exist today," said CCMB scientist Dr Jahnavi Joshi. The researchers found a high disparity in how species are formed or lost across groups of animals and plants. They found evolutionarily related groups, such as different kinds of lizards, exhibited similar rates of forming and losing species. Tired of too many ads? go ad free now They also found that half of animal and plant groups accumulated diversity gradually over millions of years. "The stability of the tropical forest ecosystems in Peninsular India has allowed for such steady diversification. As a result, this area has served as a refuge for species from severe climate changes," said Joshi. Pragyadeep Roy, first author of the study, added: "The stability of this ecosystem is surprising given the turbulent geo-climatic past of the landmass. Peninsular India was once part of the Gondwanaland supercontinent with land masses such as Africa and Australia. It broke away 100 million years ago, drifted northward, and collided with Asia, forming the Himalayas. Despite drastic geo-climatic shifts from this movement, the biodiversity changed steadily. This highlights the resilience of its forest habitats." "Global temperatures have been very dynamic across millions of years, and our analysis suggests earth's temperature strongly influences how species are formed in many groups," explained Roy. The study found that some groups experienced abrupt changes in the rates of forming new species within the time range of 11 to 3 million years ago. "This period was marked by high aridification and monsoon seasonality in Peninsular India with a major expansion of grasses, leading to shrinkage of evergreen forests to the Western Ghats and mountaintops of the Eastern Ghats. These events inflicted changes in the ranges and habitats of organisms, disrupting their earlier evolutionary trends," the study said.
United News of India
21 hours ago
- United News of India
Dr Jitendra Singh launches National BioBank' for personalised healthcare for every Indian
New Delhi, July 6 (UNI) Union Minister of State for Science and Technology and Vice President of CSIR, Dr. Jitendra Singh, today inaugurated the Phenome India National Biobank National aiming to promise personalised healthcare for every Indian based on their genetic background, lifestyle and envirornment. Designed on the lines of the UK Biobank but contextualised for Indian diversity, the biobank will collect and analyse genetic, lifestyle and clinical data from 10,000 individuals across the country. It is housed at the Council of Scientific and Industrial Research - Institute of Genomics and Integrative Biology (CSIR-IGIB) here. Dr Singh who also launched India's first longitudinal population health study on the occasion, said, 'This is a decisive step towards individualised healthcare, one where treatment can be tailored to a person's genetic background, lifestyle and environment.' The Biobank will support long-term research into a host of conditions including diabetes, cardiovascular disorders, rare genetic diseases and cancers, with a view to improve diagnostics, therapeutic targeting and disease prevention strategies, said a statement from the Ministry. Highlighting the unique metabolic and epidemiological characteristics observed in the Indian population, Dr. Singh underscored the need for population-specific strategies. 'Indians may appear lean but still harbour central obesity, a known risk factor for diabetes and cardiovascular diseases,' he noted. 'Our conditions are complex and deeply heterogeneous. This is where the Biobank becomes vital.' CSIR-IGIB's current projects, including indigenous CRISPR trials for sickle cell anaemia, efforts against antimicrobial resistance (AMR), and diagnostics for liver fibrosis and rare disorders, are expected to greatly benefit from the high-resolution health data generated through the Biobank. Calling for enhanced synergy between research institutions, government departments and the private sector, Dr. Singh emphasised the need to bridge lab-based research with social impact. 'Scientific breakthroughs must transition from the bench to the bedside—and ultimately to the marketplace,' he said. Dr. N. Kalaiselvi, Director General of CSIR and Secretary, DSIR, emphasised its potential to evolve into a global benchmark. 'This is a baby step today, but it holds the promise to rival international projects in both scale and depth,' she said. Dr. Kalaiselvi also reiterated CSIR's efforts in developing affordable diagnostics and CRISPR-based therapies in collaboration with tribal communities, particularly for sickle cell anaemia—a disease with high prevalence in certain regions of India. Reflecting on IGIB's pioneering legacy in genomics, Dr. Souvik Maiti, Director of CSIR-IGIB, noted that the institute was the first in India to begin decoding the human genome, even before sequencing tools became widely available. He cited IGIB's development of over 300 genetic diagnostics, its leadership in COVID-19 genome surveillance, and India's first Drug Genome Project. IGIB's expanding research now includes women-centric studies, breast cancer genomics, and innovative work in space biology and AI-assisted pilot fitness assessments in collaboration with the Indian Air Force, said the statement. UNI AJ GNK
The Hindu
2 days ago
- The Hindu
What are the lessons from Telangana blast?
The story so far: On the morning of June 30 at 9.10 a.m., an explosion tore through Sigachi Industries, a pharmaceutical factory, and flattened a three-storeyed building in Pashamylaram on the outskirts of Hyderabad. The stock market-listed entity estimated the death toll at 39 of the 143 workers who were on-site during the explosion. What happened? A four-member committee is investigating the cause of the explosion. The committee is led by B. Venkateshwar Rao, emeritus scientist at CSIR-IICT, and includes T. Prathap Kumar, chief scientist at CSIR-IICT; Surya Narayana, retired scientist at CSIR-CLRI; and Santosh Ghuge, safety officer at CSIR-NCL, Pune. While the cause is being investigated, the pharmaceutical company has issued a statement, 'The accident was not caused by the reactor explosion.' Sigachi Industries was incorporated in 1989 and was in the business of manufacturing microcrystalline cellulose. This is nothing more than refined wood pulp or powder. This powder is shaped into tablets and serves as an excipient or a non-reactive carrier of medicine. The wood pulp or slurry is processed in a spray dryer that strips it of moisture using hot air. Once processed like this, the wood pulp turns into a fine powder or microcrystalline cellulose. This fine powder is suspected to have blown up on that fateful Monday morning. One of the first such 'dust explosions' recorded was in Turin in Italy in 1785 when a boy working with flour in a bakery created a cloud of flour that got lit by the lamplight. Two persons, including the boy, were injured. There is a long record of similar dust explosions in flour mills, coal mines, and grain silos killing dozens across the world. Fire forensic experts say the blast at Sigachi was a dust explosion considering the scale of damage, raw materials used and processes involved. Initially, the explosion was suspected to be a Boiling Liquid Expanding Vapour Explosion, a technical term regarding the pressure built up inside the reactor. But this has been ruled out by the company, as well as experts. Was there a regulatory failure? The laxity of the regulatory framework was stark on the day of the explosion. When fire department and emergency personnel rushed to the site they did not have any information about what they were up against. The State and central pollution control boards mandate a board outside factory premises listing details about the pollution potential of the institution and factory operations. The fire fighting and disaster rescue operations are guided by this information. The green board or environment display boards outside the Sigachi Industries did not have proforma environmental data leaving fire and disaster rescue workers clueless about the nature of material involved and how to douse the fire. A tough regulatory framework with periodic check-ups would have ensured that information was available for a faster emergency response. This incident comes close on the heels of other serious accidents in pharmaceutical firms in India. Six persons were killed in Sangareddy in the SB Organics factory in 2024, 17 were killed in August 2024 in Anakapalli in Andhra Pradesh, and two were killed in Parawada, Andhra Pradesh in June 2025. What are the implications for the sector? An American investments and real estate company in its April 2025 report said: 'Telangana has emerged a pivotal contributor to India's life sciences landscape accounting for approximately one third of the country's pharmaceutical production, one fifth of pharmaceutical exports, and one third of global vaccine production. The State's position as a pharmaceutical manufacturing hub has attracted significant investments, with over $1.49 billion channelled into the life sciences sector over the past four years.' It also analysed the role of Hyderabad in this scheme of things. Over 20 life sciences and medical technology incubators are located in Hyderabad, which is the highest concentration in the country. India, with Telangana as its hub, has emerged as a powerhouse in the pharmaceutical sector. But safety and quality concerns have dogged smaller pharmaceutical firms. The U.S. is one of the biggest markets for Indian medical exports that is regulated by the U.S. Food and Drug Administration (FDA). The United States Pharmacopeia-National Formulary has a set of standards that regulate identity, strength, quality, purity, and packaging and labelling through the chain of manufacture and use. To keep being plugged into this profitable market, the standards have to match. Safety is one of the key aspects of branding for the pharmaceutical industry that helps build trust among customers. Any laxity in any aspect of the drug processing has a cascading effect for the company as well as the industry. At stake is not just the safety of one factory but the systems and workflow that are hallmarks of stable and safe drug production. Two books, The Truth Pill - The Myth of Drug Regulation in India and Bottle of Lies: Ranbaxy and the Dark Side of Indian Pharma, by Dinesh S. Thakur and Prashant Reddy T. and Katherine Eban respectively have chronicled the regulatory leeway, and documented the dangerous practices resorted to by Indian pharma firms to keep costs low and profit margins high. What about pollution control norms? Hyderabad and Telangana's pharmaceutical industry growth has been aided by lax zoning and regulatory norms. Industrial areas have to be necessarily away from residential areas. The IDA Pashamylaram was established in the early 1980s drawing some of the biggest pharmaceutical firms to the area, away from Balanagar and Patancheru that led the initial growth of the industry in Hyderabad. The initially isolated industrial area is now surrounded by residential areas. In the absence of robust and reliable public transport, worker colonies have cropped up close to the factories and industrial area. This affects the livelihood and health of people in the industrial cluster and surrounding areas. Environmentalists have documented how tonnes of toxic chemicals and effluents have been released into the ground and into water bodies around the region. The Musi River remains highly polluted with a study on 'Pharmaceutical pollution of the world's rivers' placing it in the 22nd position worldwide in terms of concentration of active pharmaceutical ingredients. This high pollution is linked to poor waste water management infrastructure, and pharmaceutical manufacturing processes. The chemicals in the water have also been linked to a rise in antimicrobial resistance. What next? The pharmaceutical sector holds the potential to attract investments and create high employment opportunities in Hyderabad and other places in India. To capitalise on this potential, India must establish a robust regulatory framework. The explosions and accidents are loud warning signs for the industry and the country.
